Altered distribution of mucosal NK cells during HIV infection.

The human gut mucosa is a major site of human immunodeficiency virus (HIV) infection and infection-associated pathogenesis. Increasing evidence shows that natural killer (NK) cells have an important role in control of HIV infection, but the mechanism(s) by which they mediate antiviral activity in the gut is unclear. Here, we show that two distinct subsets of NK cells exist in the gut, one localized to intraepithelial spaces (intraepithelial lymphocytes, IELs) and the other to the lamina propria (LP). The frequency of both subsets of NK cells was reduced in chronic infection, whereas IEL NK cells remained stable in spontaneous controllers with protective killer immunoglobulin-like receptor/human leukocyte antigen genotypes. Both IEL and LP NK cells were significantly expanded in immunological non-responsive patients, who incompletely recovered CD4+ T cells on highly active antiretroviral therapy (HAART). These data suggest that both IEL and LP NK cells may expand in the gut in an effort to compensate for compromised CD4+ T-cell recovery, but that only IEL NK cells may be involved in providing durable control of HIV in the gut

Nonintrusive electron number density measurements in the plume of a 1 kW arcjet using a modern microwave interferometer

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/77090/1/AIAA-1994-3297-662.pd

A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation

In Vitro and in vivo data have demonstrated that there are detectable differences between inhaled corticosteroids commonly used to treat asthma. However, controversy still remains as to whether these differences translate into clinical benefits. This 12-week, international, randomized, doubleblind, parallel-group study was undertaken to compare the efficacy and safety of fluticasone propionate (FP) 800 μg daily, administered as a powder via the Diskhaler®, and budesonide (BUD) 1600 μg daily, administered using the Turbuhaler®, in adult patients with moderate-tosevere asthma. A total of 518 patients participated in the study, 256 of whom received FP and 262 BUD. Assessment of mean morning peak expiratory flow (PEF) over the 12-week treatment period revealed a statistically significant difference in efficacy between FP 800 μg daily and BUD 1600 μg daily in favour of FP (p = 0.003), with an overall improvement of 20.9 l/min with FP compared with 12.4 l/min on BUD. Statistically significant differences in favour of FP were seen over the 12 weeks for mean evening PEF (p = 0.04), diurnal PEF variation (p = 0.03) and percentage predicted PEF (p = 0.003), as well as forced expiratory volume (p = 0.008), forced vital capacity (p = 0.02) and PEF (p = 0.005) measured at clinic visits. The median percentage of symptom-free nights increased over the 12-week study period in both treatment groups, with similar changes seen for the median percentage of days with symptom score < 2, rescue medication use and exacerbations of asthma. The incidence of adverse events was found to be comparable in the two treatment groups. The geometric mean ratios of serum cortisol levels were found to be 1.03 for FP, indicating no mean hypothalamic-pituitary-adrenal axis suppression from baseline, and 0.93 for BUD (p = 0.0002 compared with FP). In summary, FP 800 μg daily showed a greater efficacy/safety ratio in the treatment of moderate-to-severe asthma than BUD 1600 μg daily

Neoclassical tearing modes on AUG: improved scaling laws, high confinement at high β_N and new stabilization experiments

The accuracy of the scaling laws derived so far for the normalised beta values at the onset of neoclassical tearing modes is limited as the results depend on the presence and magnitude of seed islands. Therefore power ramp down experiments have been performed on ASDEX Upgrade, allowing to find a scaling law for the critical β value at which the NTMs disappear. For (m,n)=(3,2) NTMs these critical beta values have been found to scale nearly proportional to ρ*. As it has been recently found on ASDEX Upgrade, at high βN values there is a regime in which (3,2) NTMs cause a much smaller confinement degradation as one would expect from the β dependence of the saturated island size. The transition to this regime allows high confinement (H = 1) at high beta values ( βN > 2.3) on ASDEX Upgrade in spite of the presence of (3,2) NTMs. The plasma conditions for the transition into such a high confinement regime are discussed in detail. Furthermore, new results on NTM stabilization by localized ECCD will be presented, showing that NTMs remain stabilized even with increased heating power and thus normalized beta values well above the NTM threshold